| Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in … MV Mateos, PG Richardson, R Schlag, NK Khuageva, MA Dimopoulos, ... Journal of Clinical Oncology 28 (13), 2259-2266, 2010 | 571 | 2010 |
| Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study MV Mateos, JM Hernández, MT Hernández, NC Gutiérrez, L Palomera, ... Blood 108 (7), 2165-2172, 2006 | 537 | 2006 |
| Influence of pre-and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are … JJ Lahuerta, MV Mateos, J Martínez-López, L Rosinol, A Sureda, ... Journal of Clinical Oncology 26 (35), 5775-5782, 2008 | 354 | 2008 |
| Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 … MA Dimopoulos, E Terpos, M Boccadoro, S Delimpasi, M Beksac, ... The Lancet Oncology 22 (6), 801-812, 2021 | 266 | 2021 |
| Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma C Perez, C Botta, A Zabaleta, N Puig, MT Cedena, I Goicoechea, ... Blood, The Journal of the American Society of Hematology 136 (2), 199-209, 2020 | 97 | 2020 |
| Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data A Mosquera Orgueira, MS González Pérez, JÁ Díaz Arias, ... Leukemia 35 (10), 2924-2935, 2021 | 29 | 2021 |
| DREAMM-4: Evaluating safety and clinical activity of belantamab mafodotin in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM) AK Nooka, MV Mateos Manteca, N Bahlis, K Weisel, A Oriol, ... Hemasphere 4 (S1), 433-434, 2020 | 18 | 2020 |
| A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies MA Dawson, G Borthakur, BJP Huntly, A Karadimitris, A Alegre, ... Clinical Cancer Research 29 (4), 711-722, 2023 | 10 | 2023 |
| MagnetisMM-7: An open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma. MV Mateos Manteca, S Grosicki, K Kim, E Negre, E Vandendries Journal of Clinical Oncology 41 (16_suppl), TPS8066-TPS8066, 2023 | 8 | 2023 |
| Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation FA de la Fuente, MS Durán, MÁ Álvarez, IL Sanromán, AM Dios, ... Seminars in hematology 55 (4), 189-196, 2018 | 6 | 2018 |
| Prognostic impact of pre-transplantation computed tomography and 67gallium scanning in chemosensitive diffuse large B cell lymphoma patients undergoing … IG Escobar, PT Alonso, DC Barrigon, JA Perez-Simon, ... Annals of nuclear medicine 22, 251-260, 2008 | 4 | 2008 |
| Tratamiento del mieloma múltiple asintomático: recomendaciones del Grupo Español de Mieloma MV Mateos, J Bladé, JJ Lahuerta, J San-Miguel Med. clín (Ed. impr.), 517-523, 2017 | 3 | 2017 |
| Cystatin C‐Based Equations Detect Hidden Kidney Disease and Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma FJ Cepeda-Piorno, E González-García, A Méndez-Gallego, ... Advances in Hematology 2022 (1), 4282226, 2022 | 2 | 2022 |
| DREAMM-7: A phase III study of the efficacy and safety of belantamab mafodotin with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma R Rifkin, K Boyd, S Grosicki, K Kim, F Di Raimondo, M Dimopoulos, ... BRITISH JOURNAL OF HAEMATOLOGY 193, 172-173, 2021 | 1 | 2021 |
| Prognostic value of different echocardiographic and cardiac magnetic resonance parameters in patients with AL amyloidosis A Hernandez Martos, R Eiros Bachiller, V Gonzalez Calle, E Alejo Alonso, ... European Heart Journal 44 (Supplement_2), ehad655. 1881, 2023 | | 2023 |
| Multiple myeloma and t (11; 14): prognostic significance and impact of novel agents on response and survival. B Puertas, V González-Calle, E Sobejano, F Escalante, B Rey-Bua, ... | | 2022 |
| Poster: MM-293: Early Relapse After Autologous Stem Cell Transplant in Multiple Myeloma: Single-Center Experience in Salamanca, Spain F Peña-Muñoz, L Román-Molano, D Palomino-Mendoza, ... Clinical Lymphoma Myeloma and Leukemia 21, S254, 2021 | | 2021 |
| MM-293: Early Relapse After Autologous Stem Cell Transplant in Multiple Myeloma: Single-Center Experience in Salamanca, Spain F Peña-Muñoz, L Román-Molano, D Palomino-Mendoza, ... Clinical Lymphoma Myeloma and Leukemia 21, S433, 2021 | | 2021 |
| FACTORS WITH PROGNOSTIC IMPACT ON SYSTEMIC AMYLOIDOSIS WITH CARDIAC INVOLVEMENT. EXPERIENCE AT THE UNIVERSITY HOSPITAL OF SALAMANCA V Higuero-Saavedra, V Gonzalez-Calle, E Sobejano-Fuertes, ... HAEMATOLOGICA 104, 16-16, 2019 | | 2019 |
| SUBOPTIMAL TREATMENT ADAPTED TO THE CLINICAL SITUATION OF PATIENTS WITH MM OF NEW DIAGNOSIS TRANSPLANT CANDIDATES M Fonseca Santos, E Sobejano Fuertes, N Puig Moron, ... HAEMATOLOGICA 104, 408-408, 2019 | | 2019 |
